NCT06545110View on ClinicalTrials.gov

Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

October 30, 2024

Conditions
Alopecia Areata
Interventions
DRUG

Baricitinib Oral Tablet

Baricitinib 2/4mg giving to patients with sever alopecia areata after assessment Retinol Binding Protein 4 and its genetic variations.

Trial Locations (1)

+20963211279

South Valley University, Qina

All Listed Sponsors
lead

South Valley University

OTHER